alexa Inflectra-our Experience On Immunogenicity (case Series)
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Rodica Olteanu, Alexandra Zota and Magda Constantin
Colentina Clinical Hospital, Romania
Posters & Accepted Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-027
Biosimilars represent a new tendency in the treatment of many immune-mediated inflammatory diseases, including psoriasis. Regulatory requirements for approval of biosimilars are different from those of originators and rely mostly upon the evidence generated from bioequivalence studies and in particular from RCT, as an important part of it. In our study, case series, we tried to correlate the immunogenicity (measured with ELISA method: Antidrug antibodies and drug level) on 8 patients on Inflectra (infliximab biosimilar), treated more than 8 months in our Dermatology Clinic. Our goal was to determine the evolution of the inflammatory markers (ESR, PCR) together with the evolution of PASI, PASI50 and PASI 90 in a case series of 8 patients for 8 month. We were also capable of evaluating the possible correlations between these indices and immunogenicity. We found an interesting fact that from these 8 patients, 2 had sub-therapeutically drugged level but not antiinfliximab antibodies. One of these 2 patients had also elevated inflammatory markers and the other one has gained more than 10 kg. It was also observed that the third patient developed anti-infliximab-antibodies as well as sub-therapeutically trough level of infliximab. Two months later we evaluated the same parameters and we found no anti-infliximab antibodies. There are some discussions in the literature regarding the transient anti-drug antibodies and therefore the need to repeat them when positive and mainly when the clinical appearance does not explain the paraclinical findings. Our study concluded that, even on small clinical trial you can find valuable information that can help to tailor the treatment for the patient.

Rodica Olteanu is a Dermatologist and Medical Director of Colentina Clinical Hospital, Bucharest, Romania. She received her PhD in 2007 from Hamburg University. She is involved in autoimmunity and immunogenicity of biologics and biosimilars. She has published more than 100 papers related to lupus and psoriasis. She is the winner of many international grants, member in EADV Project Committee, AAD, GRAPPA, EuSCLE, SRD and ILDS. She completed her educational training from Barcelona and has also visited many institutes as an Invited Speaker.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version